Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants-Reference-Cited by-同舟云学术

Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants

Published:2021-04-21 Issue:7 Volume:37 Page:1149-1153
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Paes Bosco¹^ORCID,Fullarton John R.²,Rodgers-Gray Barry S.²^ORCID,Carbonell-Estrany Xavier³^ORCID

Affiliation:

1. Department of Pediatrics (Neonatal Division), McMaster University, Hamilton, Canada

2. Violicom Medical Limited, Aldermaston, UK

3. Neonatology Service, Hospital Clinic, Institut d’Investigacions Biomediques August Pi Suñer (IDIBAPS), Barcelona, Spain

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1911974

Reference26 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

2. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease

3. Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies

4. Office for National Statistics. Births by gestational age at birth, England and Wales [Internet]. 2018 [cited 2020 Dec 14]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/adhocs/10766birthsbygestationalageatbirthenglandandwales2018

5. Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants;Frontiers in Pediatrics;2024-01-12

2. Respiratory Syncytial Virus Infections in Neonates: A Persisting Problem;Newborn;2023-09-25

3. Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants;Journal of Medical Economics;2023-05-02

4. Comparison of the Canadian vs. the international risk scoring tool for respiratory syncytial virus prophylaxis in moderate-to-late preterm infants;Frontiers in Pediatrics;2023-01-05

5. Machine learning early prediction of respiratory syncytial virus in pediatric hospitalized patients;Frontiers in Pediatrics;2022-08-04